Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody engineered to concurrently target and inhibit the human epidermal growth factor receptor 2 (HER2) and the programmed death receptor-1 (PD-1). By binding to these receptors, Fidasimtamab disrupts downstream signaling pathways, thereby exerting potential immunosuppressive and antitumor effects. This antibody facilitates the linkage of PD-1 expressing T cells to HER2 expressing tumor cells, enhancing immune-mediated tumor cell killing. Fidasimtamab is under investigation for its therapeutic efficacy in various oncological applications.
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody engineered to concurrently target and inhibit the human epidermal growth factor receptor 2 (HER2) and the programmed death receptor-1 (PD-1). By binding to these receptors, Fidasimtamab disrupts downstream signaling pathways, thereby exerting potential immunosuppressive and antitumor effects. This antibody facilitates the linkage of PD-1 expressing T cells to HER2 expressing tumor cells, enhancing immune-mediated tumor cell killing. Fidasimtamab is under investigation for its therapeutic efficacy in various oncological applications.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
